Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity

Medicine

Volumn 87, Issue 2, 2008, Pages 70-86

  Bingham, April ^a,e   Mamyrova, Gulnara ^a   Rother, Kristina I ^b   Oral, Elif ^b,f   Cochran, Elaine ^b   Premkumar, Ahalya ^c   Kleiner, David ^d   James Newton, Laura ^a   Targoff, Ira N ^g   Pandey, Janardan P ^h   Carrick, Danielle Mercatante ^a   Sebring, Nancy ^c   O'Hanlon, Terrance P ^a   Ruiz Hidalgo, Maria ^i,l   Turner, Maria ^d   Gordon, Leslie B ^j   Laborda, Jorge ⁱ   Bauer, Steven R ⁱ   Blackshear, Perry J ^a   Imundo, Lisa ^k,l   Miller, Frederick W ^a   Rider, Lisa G ^a   more..

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c CLINICAL CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^j BROWN UNIVERSITY   (United States)

^k Och Spine at New York Presbyterian Hospitals   (United States)

^l Universidad de Castilla La Mancha   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYTOKINE; INSULIN RECEPTOR ANTIBODY; LAMIN; NEPHRITIC FACTOR; P155 AUTOANTIBODY; UNCLASSIFIED DRUG;

ACANTHOSIS NIGRICANS; ADOLESCENT; ADOLESCENT HEALTH; ARTICLE; CALCINOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE COURSE; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENE MUTATION; HIGH RISK POPULATION; HIRSUTISM; HUMAN; IMMUNOGENICITY; INSULIN RESISTANCE; JOINT CONTRACTURE; LIPODYSTROPHY; MALE; MORBIDITY; MUSCLE ATROPHY; NONALCOHOLIC FATTY LIVER; PANNICULITIS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RASH; SCHOOL CHILD; STEATOSIS;

ACANTHOSIS NIGRICANS; ADOLESCENT; ADULT; AUTOANTIBODIES; BIOLOGICAL MARKERS; BODY FAT DISTRIBUTION; CALCINOSIS; CASE-CONTROL STUDIES; CHILD; CONTRACTURE; DERMATOMYOSITIS; EXANTHEMA; FACIAL DERMATOSES; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HIRSUTISM; HUMANS; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPODYSTROPHY; MALE; MUSCULAR ATROPHY; PANNICULITIS; PHENOTYPE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 40949124812     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/MD.0b013e31816bc604     Document Type: Article

References (63)

1. Agarwal AK, Garg A. Genetic basis of lipodystrophies and management of metabolic complications. Annu Rev Med. 2006;57:297-311.
2. Agarwal AK, Garg A. Genetic disorders of adipose tissue development, differentiation, and death. Annu Rev Genomics Hum Genet. 2006;7:175-199.
3. Ahmed ML, Ong KK, Morrell DJ, Cox L, Drayer N, Perry L, Preece MA, Dunger DB. Longitudinal study of leptin concentrations during puberty: sex differences and relationship to changes in body composition. J Clin Endocrinol Metab. 1999;84:899-905.
4. American Academy of Pediatrics. National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics. 1992;89:525-584.
5. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus [Position Statement]. Diabetes Care. 2007;30(Suppl 1):S42-S47.
6. Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI, Gorden P. Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore). 2002;81:87-100.
7. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman, Herion D, Kleiner DE, Reynolds J, Premkumar A, Sumner AE, Hoofnagle J, Reitman ML, Taylor SI. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med. 2000;133:263-274.
8. Boguslavsky RL, Stewart CL, Worman HJ. Nuclear lamin A inhibits adipocyte differentiation: implications for Dunnigan-type familial partial lipodystrophy. Hum Mol Genet. 2006;15:653-663.
9. Carrick DM, Chulada P, Donn R, Fabris M, McNicholl J, Whitworth W, Blackshear PJ. Genetic variations in ZFP36 and their possible relationship to autoimmune diseases. J Autoimmun. 2006;26:182-196.
10. Chumlea WC, Guo SS, Kuczmarski RJ, Flegal KM, Johnson CL, Heymsfield SB, Lukaski HC, Friedl K, Hubbard VS. Body composition estimates from NHANES III bioelectrical impedance data. Int J Obes Relat Metab Disord. 2002;26:1596-1609.
11. Cohen HL, Tice HM, Mandel FS. Ovarian volumes measured by US: bigger than we think. Radiology. 1990;177:189-192.
12. den Dunnen JT, Antonarakis SE. Nomenclature for the description of human sequence variations. Hum Genet. 2001;109:121-124.
13. Diehl AM. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:619-638.
14. Dinges WL, Chen D, Snell PG, Weatherall PT, Peterson DM, Garg A. Regional body fat distribution in HIV-infected patients with lipodystrophy. J Investig Med. 2005;53:15-25.
15. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, Dutra A, Pak E, Durkin S, Csoka AB, Boehnke M, Glover TW, Collins FS. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 2003;423:293-298.
16. Ettinger WH, Goldberg AP, Applebaum-Bowden D, Hazzard WR. Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med. 1987;83:503-508.
17. Ettinger WH Jr, Hazzard WR. Prednisone increases very low density lipoprotein and high density lipoprotein in healthy men. Metabolism. 1988;37:1055-1058.
18. Fardet L, Cabane J, Kettaneh A, Lebbe C, Flahault A. Corticosteroid- induced lipodystrophy is associated with features of the metabolic syndrome. Rheumatology. 2007;46:1102-1106.
19. Fawcett RL, Waechter AS, Williams LB, Zhang P, Louie R, Jones R, Inman M, Huse J, Considine RV. Tumor necrosis factor-alpha inhibits leptin production in subcutaneous and omental adipocytes from morbidly obese humans. J Clin Endocrinol Metab. 2000;85:530-535.
20. Feve B. Adipogenesis: cellular and molecular aspects. Best Pract Res Clin Endocrinol Metab. 2005;19:483-499.
21. Formiga F, Meco JF, Pinto X, Jacob J, Moga I, Pujol R. Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus. 2001;10:359-363.
22. Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350:1220-1234.
23. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160-3167.
24. Gottschling-Zeller H, Birgel M, Scriba D, Blum WF, Hauner H. Depot-specific release of leptin from subcutaneous and omental adipocytes in suspension culture: effect of tumor necrosis factor-alpha and transforming growth factor-beta1. Eur J Endocrinol. 1999;141:436-442.
25. Grundy SM. Approach to lipoprotein management in 2001 National Cholesterol Guidelines. Am J Cardiol. 2002;90(8A):11i-21i.
26. Hall SK, Perregaux DG, Gabel CA, Woodworth T, Durham LK, Huizinga TW, Breedveld FC, Seymour AB. Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta protein. Arthritis Rheum. 2004;50:1976-1983.
27. Harlow E, Lane D. Antibodies: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1988.
28. He W, Dorn DC, Erdjument-Bromage H, Tempst P, Moore MA, Massague J. Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell. 2006;125:929-941.
29. Holm S. A simple sequentially rejective multiple test procedure. Scand J Statist. 1979;6:65-70.
30. Huang JL. Juvenile dermatomyositis associated with partial lipodystrophy. Br J Clin Pract. 1996;50:112-113.
31. Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, MacNeil I, Momy JA, Avery G, Feldman BM. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum. 2000;43:541-549.
32. Huemer C, Kitson H, Malleson PN, Sanderson S, Huemer M, Cabral DA, Chanoine JP, Petty RE. Lipodystrophy in patients with juvenile dermatomyositis - evaluation of clinical and metabolic abnormalities. J Rheumatol. 2001;28:610-615.
33. Ilowite NT, Samuel P, Ginzler E, Jacobson MS. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum. 1988;31:859-863.
34. Jacob KN, Garg A. Laminopathies: multisystem dystrophy syndromes. Mol Genet Metab. 2006;87:289-302.
35. Kavanagh GM, Colaco CB, Kennedy CT. Juvenile dermatomyositis associated with partial lipoatrophy. J Am Acad Dermatol. 1993;28:348-351.
36. Laborda J. The role of the epidermal growth factor-like protein dlk in cell differentiation. Histol Histopathol. 2000;15:119-129.
37. Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum. 1997;40:865-874.
38. McCann LJ, Juggins AD, Maillard SM, Wedderburn LR, Davidson JE, Murray KJ, Pilkington CA. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland) - clinical characteristics of children recruited within the first 5 yr. Rheumatology. 2006;45:1255-1260.
39. McCarthy HD, Cole TJ, Fry T, Jebb SA, Prentice AM. Body fat reference curves for children. Int J Obes. 2006;30:598-602.
40. Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine (Baltimore). 2003;82:129-146.
41. Misra A, Peethambaram A, Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore). 2004;83:18-34.
42. Nueda ML, Baladron V, Garcia-Ramirez JJ, Sanchez-Solana B, Ruvira MD, Rivero S, Ballesteros MA, Monsalve EM, Diaz-Guerra MJ, Ruiz-Hidalgo MJ, Laborda J. The novel gene EGFL9/Dlk2, highly homologous to Dlk1, functions as a modulator of adipogenesis. J Mol Biol. 2007;367:1270-1280.
43. O'Hanlon TP, Carrick DM, Arnett FC, Reveille JD, Carrington M, Gao X, Oddis CV, Morel P, Malley JD, Malley, K, Dreyfuss J, Shamim EA, Rider LG, Chanock SJ, Foster CB, Bunch T, Plotz PH, Love LA, Miller FW. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in caucasians. Medicine (Baltimore). 2005;84:338-349.
44. Park JY, Javor ED, Cochran EK, DePaoli AM, Gorden P. Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy. Metabolism. 2007;56:508-516.
45. Parks CG, Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS, Pandey JP. Systemic lupus erythematosus and genetic variation in the interleukin 1 gene cluster: a population based study in the southeastern United States. Ann Rheum Dis. 2004;63:91-94.
46. Parks CG, Pandey JP, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS, Feghali-Bostwick CA, Cooper GS. Genetic polymorphisms in tumor necrosis factor (TNF)-alpha and TNF-beta in a population-based study of systemic lupus erythematosus: associations and interaction with the interleukin-1alpha-889 C/T polymorphism. Hum Immunol. 2004;65:622-631.
47. Pope E, Janson A, Khambalia A, Feldman B. Childhood acquired lipodystrophy: a retrospective study. J Am Acad Dermatol. 2006;55:947-950.
48. Premkumar A, Chow C, Bhandarkar P, Wright V, Koshy N, Taylor S, Arioglu E. Lipoatrophic-lipodystrophic syndromes: the spectrum of findings on MR imaging. AJR Am J Roentgenol. 2002;178:311-318.
49. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004;39:188-196.
50. Quon MJ. Limitations of the fasting glucose to insulin ratio as an index of insulin sensitivity. J Clin Endocrinol Metab. 2001;86:4615-4617.
51. Reitman ML, Arioglu E, Gavrilova O, Taylor SI. Lipoatrophy revisited. Trends Endocrinol Metab. 2000;11:410-416.
52. Rider LG, Feldman BM, Perez MD, Rennebohm RM, Lindsley CB, Zemel LS, Wallace CA, Ballinger SH, Bowyer SL, Reed AM, Passo MH, Katona IM, Miller FW, Lachenbruch PA. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum. 1997;40:1976-1983.
53. Rider LG, Pachman LM, Miller FW. Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers. 1st ed. Washington, DC: The Myositis Association; 2007.
54. Ruhl CE, Everhart JE. Leptin concentrations in the United States: relations with demographic and anthropometric measures. Am J Clin Nutr. 2001;74:295-301.
55. Schwenk A. Methods of assessing body shape and composition in HIV-associated lipodystrophy. Curr Opin Infect Dis. 2002;15:9-16.
56. Simha V, Garg A. Body fat distribution and metabolic derangements in patients with familial partial lipodystrophy associated with mandibuloacral dysplasia. J Clin Endocrinol Metab. 2002;87:776-785.
57. Singh S, Bansal A. Twelve years experience of juvenile dermatomyositis in North India. Rheumatol Int. 2006;26:510-515.
58. Spuler S, Kalbhenn T, Zabojszcza J, van Landeghem FK, Ludtke A, Wenzel K, Koehnlein M, Schuelke M, Ludemann L, Schmidt HH. Muscle and nerve pathology in Dunnigan familial partial lipodystrophy. Neurology. 2007;68:677-683.
59. Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, Miller FW, Rider LG. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54:3682-3689.
60. Targoff IN, Trieu EP, Levy-Neto M, Prasertsuntarasai T, Miller FW. Autoantibodies to transcriptional intermediary factor 1-gamma (TIF1-g in dermatomyositis. Arthritis Rheum. 2006;54(Suppl):S1241.
61. Taylor GA, Carballo E, Lee DM, Lai WS, Thompson MJ, Patel DD, Schenkman DI, Gilkeson GS, Broxmeyer HE, Haynes BF, Blackshear PJ. A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity. 1996;4:445-454.
62. Valerio CM, Godoy-Matos A, Moreira RO, Carraro L, Guedes EP, Moises RS, Mory PB, de Souza LL, Russo LA, Melazzi AC. Dual-energy X-ray absorptiometry study of body composition in patients with lipodystrophy. Diabetes Care. 2007;30:1857-1859.
63. Verma S, Singh S, Bhalla AK, Khullar M. Study of subcutaneous fat in children with juvenile dermatomyositis. Arthritis Rheum. 2006;55:564-568.